Background
Methods
Calculation of aggregated summary statistics
Cohort | ΔAUC – AB | ΔAUC – AC | ΔAUC – AD |
---|---|---|---|
X | 0.05 | – | 0.07 |
Y | 0.06 | – | 0.18 |
Cohort X | ||
0.0012 | 0.0005 | |
0.0005 | 0.0009 | |
Cohort Y | ||
0.0068 | 0.0051 | |
0.0051 | 0.0109 |
Examination of network structure
g
| Scores | Cohorts |
n
|
d
|
Q
|
df
|
τ
|
---|---|---|---|---|---|---|---|
1 | A, B | R | 4000 | 350 | 28 | 0 | 0.019 |
2 | A, C | S, T | 1000 | 200 | 15.5 | 1 | 0.014 |
3 | A, B, D | U, V | 3000 | 300 | 13.4 | 2 | 0.004 |
4 | A, B, C, D | X, Y | 2000 | 300 | 9.6 | 3 | 0.036 |
Multiple score comparison
Stage |
G
| B | C | D |
---|---|---|---|---|
I | 1 | 0.09 (0.07, 0.12) | ||
I | 2 | 0.18 (0.07, 0.29) | ||
I | 3 | 0.10 (0.08, 0.12) | 0.22 (−0.05, 0.50) | |
I | 4 | 0.08 (0.04, 0..12) | 0.15 (0.01, 0.29) | 0.18 (0.05, 0.31) |
II | 0.09 (0.06, 0.13) | 0.17 (0.10, 0.25) | 0.21 (0.07, 0.35) |
Transitivity, heterogeneity and inconsistency
Consideration of missing data
COPD data description
Results
Examination of network structure
g | Scores | Cohortsa
|
n
|
d
|
Q
|
df
|
τ
|
---|---|---|---|---|---|---|---|
1 | GOLD – ADO | Copenhagen*, HUNT, Japan, SEPOC* | 4323 | 378 | 2.8 | 3 | 0 |
2 | GOLD – ADO – BODE – BODEupd | Barmelweid*, Basque*, Galdakao†, Pamplona†, Zaragoza I† | 1208 | 215 | 15.5 | 12 | 0.014 |
3 | GOLD – GOLD (2011) – ADO – BODE – BODEupd | Mar de Plata Argentina, PACECOPD*, Son Espases Mallorca | 556 | 61 | 10.9 | 8 | 0.025 |
4 | GOLD – GOLD (2011) – ADO – BODE – BODEupd – SAFE | COPDgene | 4484 | 337 | 7.46E-29 | 0 | NA |
5 | GOLD – GOLD (2011) – ADO – BODEx – DOSE – BAED | Genkols, ICE COLD ERIC, Initiatives BPCO, Sevilla†, Terrassa I†, Terrassa III†, Zaragoza II† | 4346 | 722 | 48.1 | 30 | 0.011 |
6 | GOLD – GOLD (2011) – ADO – BODE – BODEupd – eBODE – BODEx – DOSE – BAED | La Princesa Madrid, Requena II†, Tenerife†, Terrassa II† | 845 | 125 | 34.5 | 24 | 0.014 |
Multiple score comparison meta-analysis (MSC)
Transitivity, heterogeneity and inconsistency
Stage | g | ADO | BODEupd | eBODE | BODE | SAFE | BODEx | DOSE | BAED | newGOLD |
---|---|---|---|---|---|---|---|---|---|---|
I | 1 | 0.097 (0.07, 0.123) | ||||||||
I | 2 | 0.098 (0.057, 0.139) | 0.124 (0.078, 0.17) | 0.098 (0.059, 0.137) | ||||||
I | 3 | 0.044 (−0.03, 0.117) | 0.023 (−0.054, 0.099) | 0.019 (−0.054, 0.091) | −0.011 (−0.053, 0.03) | |||||
I | 4 | 0.042 (0.01, 0.074) | 0.043 (0.008, 0.078) | 0.049 (0.017, 0.081) | 0.037 (0.005, 0.069) | −0.008 (−0.038, 0.022) | ||||
I | 5 | 0.099 (0.076, 0.123) | 0.056 (0.035, 0.076) | 0.036 (0.015, 0.057) | 0.032 (0.005, 0.058) | 0.028 (0.008, 0.047) | ||||
I | 6 | 0.076 (0.027, 0.126) | 0.043 (−0.006, 0.092) | 0.048 (0.004, 0.093) | 0.043 (0.001, 0.085) | 0.030 (−0.015, 0.074) | 0.021 (−0.023, 0.065) | −0.017 (−0.079, 0.045) | 0.008 (−0.031, 0.047) | |
II | 0.083 (0.069, 0.097) | 0.072 (0.051, 0.093) | 0.069 (0.044, 0.093) | 0.064 (0.045, 0.082) | 0.052 (0.022, 0.082) | 0.045 (0.029, 0.061) | 0.027 (0.010, 0.045) | 0.016 (−0.007, 0.038) | 0.014 (0.001, 0.028) |
Discussion
Conclusions
Acknowledgements
Funding
Availability of data and materials
Ethics approval and consent to participate
-
de Torres JP, Casanova C, Marin JM, et al. Prognostic evalation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014; 69: 799–804.
-
Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704–11.
-
Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7: 32–43.
-
Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530–35.
-
Puhan MA, Hansel NN, Sobradillo P, et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open 2012; 2: e002152.
-
Esteban C, Quintana JM, Aburto M, et al. The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients. Respir Med 2011; 105: 1662–70.
-
Johannessen A, Nilsen RM, Storebo M, Gulsvik A, Eagan T, Bakke P. Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med 2013; 188: 51–59.
-
Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifi cations and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax 2013; 68: 914–21
-
Frei A, Muggensturm P, Putcha N, et al. Five comorbidities refl ected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. J Clin Epidemiol 2014; 67: 90–111.
-
Roche N, Deslee G, Caillaud D, et al. Impact of gender on COPD expression in a real-life cohort. Respir Res 2014; 15: 20.
-
Garcia-Aymerich J, Gomez FP, Benet M, et al. Identifi cation and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011; 66: 430–37.
-
Soler JJ, Sanchez L, Roman P, Martinez MA, Perpina M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med 2004; 98: 318–29.
-
Soler-Cataluña JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
-
Soler-Cataluña JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692–99.
-
Alfageme I, Reyes N, Merino M, et al. The eff ect of airfl ow limitation on the cause of death in patients with COPD. Chron Respir Dis 2010; 7: 135–45.
-
Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591–97.
-
Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–48.
-
Sanjaume M, Almagro P, Rodriguez-Carballeira M, Barreiro B, Heredia JL, Garau J. Post-hospital mortality in patients re-admitted due to COPD. Utility of BODE index. Rev. Clin Esp 2009; 209: 364–70 (in Spanish).
-
Almagro P, Salvado M, Garcia-Vidal C, et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax 2010; 65: 298–302.
-
Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325–31.
-
Pillai AP, Turner AM, Stockley RA. Global Initiative for Chronic Obstructive Lung Disease 2011 symptom/risk assessment in alpha1- antitrypsin defi ciency. Chest 2013; 144: 1152–62.